Popular
BlogNEW
CompaniesNEW
Finance
Technology
Banking
Information Technology
Oil and Energy
Internet
Mining and Metals
Communications
Real Estate
Biotechnology
Automotive
Medical
Retail
Energy
Q3 2021 Investor Relations Results slide image

Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Particularly strong YTD growth for key brands Cosentyx® Entresto zolgensma® KISQALI ribociclib 1 GROWTH Kesimpta USD 3.5bn +18% USD 2.6bn USD 1.0bn +41% +49% USD 0.7bn +27% USD 0.2bn nm All growth rates in constant currencies (cc) 8 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine
View entire presentation

Product

HomeSearchAccount

Categories

Finance PresentationsTechnology PresentationsBanking PresentationsInformation Technology PresentationsOil and Energy PresentationsInternet PresentationsMining and Metals PresentationsCommunications PresentationsReal Estate PresentationsBiotechnology PresentationsAutomotive PresentationsMedical PresentationsRetail PresentationsEnergy Presentations

Company

InsightsContactSupport

Legal

Terms of ServicePrivacy Policy

Connect

TwitterLinkedInInstagramYouTube